Skip to main content

Table 3 Reasons for discontinuation of 5GPE-SLIT before the end-of-study follow-up visit

From: An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France

 

Children

(N = 203)

Adults

(N = 280)

Total

(N = 483)

Discontinuation before the start of the pollen season

N = 18

N = 34

N = 52

 Planned end of treatment course

1 (5.6%)

2 (5.9%)

3 (5.8%)

 Patient decision

2 (11.1%)

3 (8.8%)

5 (9.6%)

 Occurrence of an adverse event

14 (77.8%)

27 (79.4%)

41 (78.8%)

 Other

1 (5.6%)

2 (5.9%)

3 (5.8%)

Discontinuation after the start of the pollen season

N = 150

N = 191

N = 341

 Planned end of treatment course

136 (90.7%)

172 (90.1%)

308 (90.3%)

 Patient decision

5 (3.3%)

8 (4.2%)

13 (3.8%)

 Lack of efficacy

1 (0.7%)

1 (0.5%)

2 (0.6%)

 Occurrence of an adverse event

None

2 (1.0%)

2 (0.6%)

 Other

3 (2.0%)

1 (0.5%)

4 (1.2%)

 Not documented

5 (3.3%)

7 (3.7%)

12 (3.5%)

  1. Reasons for discontinuation are not mutually exclusive and more than one reason can this be documented in any given patient